Disposición ANMAT 224/2026: Used and Refurbished Device Import Framework
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Disposición ANMAT 224/2026, published on February 2, 2026, establishes a new import framework for used and refurbished medical devices. Its core move is to repeal Disposición 806/2007 and abolish the certificate for the import of used goods (CIBU). The CIBU had functioned as an additional pre-approval gate for every used-equipment shipment, and its removal removes an entire layer of front-end administration from the import chain.
The framework covers three import scenarios: ① import after refurbishment abroad; ② import of used equipment that requires no mandatory refurbishment; ③ import into Argentina followed by refurbishment within the country. The circle of eligible importers widens at the same time — end users such as clinics and hospitals may now act as importers, no longer restricted to authorized companies. Widening who may import while keeping the evidence and authorization requirements intact is the defining trade-off of the new regime, and both halves of it must be understood before any used-equipment shipment is planned.
2. Legal basis
| Regulation | Reference number | Publication date | Relevant provisions |
|---|---|---|---|
| Import rules for used/refurbished medical devices | Disposición ANMAT 224/2026 | Published February 2, 2026 | Three import scenarios provisions; refurbishment certificate provisions; labeling provisions; risk classification provisions |
| Repealed: former used-equipment import rules | Disposición ANMAT 806/2007 | 2007 | Full text (repealed by 224/2026) |
| Import facilitation for Class I/II products | Disposición ANMAT 4446/2025 | Published June 24, 2025, effective 30 days after publication | 48-hour import notification provisions |
| MERCOSUR technical regulation for medical device registration | GMC/RES 25/21 | October 13, 2021 | Part I (used/refurbished equipment outside the scope of application) |
3. Expert insights
Insight 1: Abolishing the CIBU is a substantive reduction of administrative burden. Previously, used-equipment imports required obtaining the CIBU first — an additional front-end approval before any shipment could move. With the certificate abolished by Disposición 224/2026, Class I/II used equipment proceeds under the 48-hour notification after customs clearance, aligning the treatment of used devices with the facilitation rules already applying to new devices of the same classes. The alignment matters operationally: teams can reuse the same notification workflow, templates, and responsible-person structure they built for new-product imports.
Insight 2: The three scenarios carry three evidence requirements, but one set of common obligations. Whichever scenario applies, the importer must provide: a refurbishment certificate issued by the original manufacturer (or an equivalent attestation), a remaining useful life assessment, and evidence of conformity with current safety and performance standards, together with a specific label marking the refurbished status. The evidence requirements are not lowered because the procedure is simplified. The simplification removes a paperwork gate; it does not dilute the technical standard the equipment itself must meet on arrival.
Insight 3: Risk classification still determines the intensity of approval. Class I/II devices follow the 48-hour notification after customs clearance; Class III/IV devices require ANMAT prior authorization. This matches the triage logic for new-product imports exactly, showing that 224/2026 is a subtraction performed within the existing risk-classification framework rather than the construction of a parallel regime. A company that already understands the new-device pathways needs to learn only the refurbishment-specific evidence layer, not a new approval architecture.
4. Practical recommendations
- First determine which of the three scenarios applies. Import after refurbishment abroad, used equipment requiring no mandatory refurbishment, and refurbishment within Argentina each carry different evidence requirements — characterize the case first, then assemble the dossier.
- Prioritize obtaining the refurbishment certificate from the original manufacturer. Where the original manufacturer cannot issue one, prepare an equivalent attestation and document its source and basis so the equivalence can be defended in an inspection.
- Quantify the remaining useful life assessment. State the equipment’s remaining years of use or number of cycles in a verifiable way, and describe the assessment method used to arrive at the figure.
- Reserve prior-authorization time for Class III/IV equipment. The import approval of high-risk used equipment must be built into logistics schedules; it cannot be estimated on a clearance-and-release basis.
5. Verification checklist
- □ Confirmed the framework of 224/2026 applies and the equipment is not an excluded item
- □ Determined which of the three import scenarios the case falls into
- □ Refurbishment certificate from the original manufacturer (or equivalent attestation) obtained
- □ Remaining useful life assessment quantified with its method documented
- □ Evidence of conformity with current safety and performance standards assembled
- □ Specific label marking the refurbished status designed and applied
- □ 48-hour notification (Class I/II) or prior authorization (Class III/IV) scheduled by class
Regulatory information verified as of October 29, 2026.
A practical note on sequencing: the three scenarios are not interchangeable labels, and misclassification is expensive to correct after documents have been commissioned. Import after refurbishment abroad puts the evidentiary weight on the original manufacturer’s certificate and the state of the equipment at export; used equipment without mandatory refurbishment leans on the remaining useful life assessment; refurbishment inside Argentina adds the domestic authorization question for whoever performs the work. Because GMC/RES 25/21 leaves used and refurbished equipment outside its scope of application, there is no regional harmonization to fall back on — the Argentine national framework of 224/2026 is the entire rulebook. Teams new to the market should therefore budget review time for the evidence layer, not only for the notification or authorization step that follows it.
In Argentina, GRZAN operates a wholly-owned subsidiary that can serve as the registration holder and importer for foreign manufacturers, directly handling classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.
The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the dynamics of regulatory authorities across countries on an ongoing basis. All external content follows the drafting standard of conclusions first, traceable bases, and verifiable figures. For an Argentina or MERCOSUR market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us